Real-World Dosing and Adverse-Event Management in Japan

Dr. Lakshmi Nayak asks Dr. Motoo Nagane about real-world patient selection and dose maintenance in Japan, drawing on several years of post-approval experience. Dr. Nagane notes the approved once-daily dose taken under fasting conditions, typically initiated as second-line monotherapy after relapse following R-MPV-based treatment, with alternatives (R-MPV rechallenge or non-methotrexate IV chemotherapy) considered for patients with interstitial lung disease or who cannot take oral medication. He emphasizes tirabrutinib's rapid response, often early in treatment, prompting early contrast-enhanced MRI and cautioning against prematurely judging treatment ineffective. On safety, he describes skin rash as a characteristic and relatively common event, more frequent in Japanese than U.S. patients, generally low-grade and appearing early in the treatment course, managed with antihistamines, topical corticosteroids, and if needed brief interruption followed by dose reduction. He routinely uses trimethoprim-sulfamethoxazole for PJP prophylaxis and acyclovir against herpesvirus, monitors for uncommon but serious interstitial pneumonitis and hepatic dysfunction, and notes generally low-grade cytopenias. Dr. Christian Grommes adds that early, aggressive treatment of rash with topical or oral steroids usually resolves it quickly.